Work

Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials

Year: 2006

Type: article

Source: Leukemia

DOI: 10.1038/sj.leu.2404442

Authors: S Jagannath, P G Richardson, P Sonneveld, M W Schuster, D Irwin, E A Stadtmauer, T Facon, J-L Harousseau, J M Cowan, K C Anderson

Institutions: Saint Vincent's Catholic Medical Center, Dana-Farber Cancer Institute, Erasmus MC, NewYork–Presbyterian Hospital, Cornell University, Abramson Cancer Center, University of Pennsylvania, Hôpital Claude Huriez, Tufts Medical Center

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Takeda Oncology

OpenAlex ID: W2029006246

FWCI: 20.51

Cites: 30

Cited by: 262

Related to: 10